Aethlon Medical Inc AEMD.OQ AEMD.O is expected to show no change in quarterly revenue when it reports results on June 26 for the period ending March 31 2025
LSEG's mean analyst estimate for Aethlon Medical Inc is for a loss of $1.01 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aethlon Medical Inc is $30.25, about 95.4% above its last closing price of $1.40
This summary was machine generated June 24 at 20:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)